BioSpace News Archive

CiToxLAB, a leading Contract Research Organization (CRO), announces the purchase of a new facility in Laval (Montreal, Canada) to meet the growing demand for bioanalysis and biomarkers services in support of preclinical and clinical programs, offering shorter lead times for development programs.

Antabio SAS announced today the completion of a 7.3M Euros series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.

The Court ordered Onxeo to pay SpeBio for costs incurred before termination the sum of 8.6 million euros with capitalized interest at the legal rate as of June 30, 2014.

ASHG17, Booth #323 -- Leading global genomics service provider, GENEWIZ, launches CLIA Sanger sequencing and new NGS amplicon sequencing, at booth #323 during The American Society of Human Genomics (ASHG) Annual Meeting.

NuVasive today announced the launch of Modulus XLIF titanium implants.

Catalent today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Catalent Operating Subsidiary”), has completed an amendment to its senior secured credit facilities to lower the interest rate on its U.S. dollar-denominated and euro-denominated term loans and its revolving loans.

Insulet is partnering with DexCom, Inc. (Dexcom) to provide the Omnipod System and a $200 gift card from Dexcom which can be used towards the purchase of a Dexcom G5 Mobile CGM (Continuous Glucose Monitoring) for qualified Animas insulin pump users.

Allergan issued the FAQ document following the U.S. District Court’s decision on the RESTASIS patents announced earlier this week.

The Bonnie J. Addario Lung Cancer Foundation (ALCF) and the International Association for the Study of Lung Cancer (IASLC) today announced the winner of the $300,000 ALCF-IASLC Second Joint International Fellowship Award for The Early Detection of Lung Cancer.

City of Hope will be one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR-T cell therapy.